Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9822355
SERIAL NO

14647547

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CHILDREN'S MEDICAL CENTER CORPORATION55 SHATTUCK STREET BOSTON MA 02115

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bauer, Daniel E Cambridge, US 17 27
Orkin, Stuart H Brookline, US 17 253
Xu, Jian Plano, US 831 9277

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 21, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 21, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00